Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update

Sarcomere Directed Therapies Exhibit

Forward-Looking Statements This

Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the

protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements related Cytokinetics' research and development and commercial readiness activities, including the

initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of clinical trials, projections regarding growing prevalence, low survival rates and market opportunity in heart failure, hypertrophic cardiomyopathy

(HCM) or amyotrophic lateral sclerosis (ALS); projections regarding the size of the addressable patient population for omecamtiv mecarbil, CK-274 or reldesemtiv; Cytokinetics' commercial readiness for omecamtiv mecarbil; the likelihood of

approval and timing for regulatory approval of omecamtiv mecarbil or any of our other drug candidates; the submission of a new drug application (NDA) to the FDA for omecamtiv mecarbil in 2021;the timing of commencement of COURAGE-ALS, a phase 3

clinical trial of reldesemtiv or the timing of commencement of a phase 3 clinical trial of CK-274; the timing of any potential commercial launch of our product candidates, if approved; commercial opportunities for our product candidates;

Cytokinetics' cash runway; interactions with the FDA; the properties, potential benefits and commercial potential of CK-274, omecamtiv mecarbil, reldesemtiv and Cytokinetics' other drug candidates. Such statements are based on

management's current expectations; but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial

commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or

preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic

efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property;

Cytokinetics may incur unanticipated research, development and other costs or be unable to obtain financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and

competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. These forward-looking statements speak only as of the date they

are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics' business, investors should consult

Cytokinetics' filings with the Securities and Exchange Commission (the "SEC").

To bring forward new medicines to

improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Sarcomere Directed Therapies OUR MISSION

Our vision is to be the leading muscle

biology biopharma company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to our pioneering medicines Achieve regulatory approvals for at least two drugs arising from our pipeline Build

commercial capabilities to market and sell our medicines reflective of their innovation and value Generate sustainable and growing revenues from product sales Double our development pipeline to include ten therapeutic programs Expand our discovery

platform to muscle energetics, growth and metabolism Be the science-driven company people want to join and partner with As always, we will support disease advocacy groups elevating the patient voice and live by our values of integrity, fairness and

compassion in all that we do. VISION Leading with Science,

Executing On Our Vision Scientific

innovation driven by modulating cardiac myosin First-in-class myosin activator Next-in-class myosin inhibitor Expansion beyond contractility to muscle energetics, metabolism Regular input, collaboration and guidance Elevate patient voice Improve

function, performance and healthspan Customer-centric approach to portfolio management Overlap between HFrEF and HCM accounts Commercial build in HFrEF supports future HCM business Lifecycle management extends and expands franchise Build a Franchise

Lead with Science Methodically Investigate Think Like a Patient Positive Phase 3 results from GALACTIC-HF; NDA submission expected in 2H 2021 Positive Phase 2 results from REDWOOD-HCM; Phase 3 clinical trial expected by year-end Clinical trial

results from METEORIC-HF expected in early 2022

Pipeline of Novel Muscle-Directed Drug

Candidates * Astellas to provide co-funding in exchange for low single-digit royalty All drug candidates above are investigational products and are not approved as safe or effective for any indication. CARDIAC MUSCLE Omecamtiv Mecarbil

(Heart Failure) CK-274 (oHCM, nHCM, HFpEF) CK-271 CK-136 (AMG 594) (Heart Failure, other) SKELETAL MUSCLE Reldesemtiv (ALS)* CK-601 Additional Skeletal Muscle Activators OTHER Muscle Biology Directed Research Research Pre-Clinical

Phase 1 Phase 2 Phase 3 Myosin-Targeted Troponin-Targeted Research

CK-274, CK-271 Omecamtiv Mecarbil

CK-136 (AMG 594) Sarcomere Directed Drug Development Cardiac MUSCLE

Contractile Dysfunction Underlies Heart

Failure Increased / Preserved Cardiac Contractility Non-obstructive Hypertrophic Cardiomyopathy (nHCM) Obstructive Hypertrophic Cardiomyopathy (oHCM) Heart Failure with Preserved Ejection Fraction (certain HFpEF subsets) Decreased Cardiac

Contractility Heart Failure with Reduced Ejection Fraction (HFrEF) Genetic Dilated Cardiomyopathy Pulmonary Hypertension with Right Ventricular Heart Failure

Sarcomere Directed Drug Development

Cardiac muscle The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force Actin Tropomyosin Myosin head Myosin lever arm Calcium ATP Thin filament Thick filament Activate

CK-136 (Cardiac) Myosin Activate Omecamtiv Mecarbil (Cardiac) Inhibit CK-274 (Cardiac) Troponin Inhibit CK-271 (Cardiac)

Sarcomere Directed Drug Development

Symptomatic HCM: Orphan Indication

Source: #26 SHA 2016-2021 Patient Claims Data; #20 Cogent HC 2020 DoF US HCM Prevalence

CK-274: Next-In-Class Cardiac Myosin

Inhibitor Potential treatment for patients with HCM Myosin Selective allosteric inhibitor of cardiac myosin discovered by company scientists independent of collaborations Potential in vivo pharmacodynamic advantages related to distinctive binding

site Optimized for Onset of action (reach steady state within two weeks) Rapid reversibility of effect Minimal drug-drug interactions Favorable tolerability Ease of titration for personalized dosing Clear pharmacokinetic/pharmacodynamic (PK/PD)

relationship observed Shallow exposure-response relationship

Preclinical data translated to

healthy participants SAD & MAD Results Support Progression to Phase 2 MAD PK: Steady-State Achieved After 14 Days of Dosing Nominal Day 0 2 4 6 8 10 12 14 16 18 20 150 100 50 0 CK-274 (ng/mL) 10 mg qy x 14d 5 mg qd x 14d Steady-state attained

Last dose Trough samples only Graphs show LVEF as a function of exposure; data points represent observed values in dogs and humans. Decrease in LVEF as function of exposure is similar in humans and dogs. PK/PD Relationship of CK-274 for Ejection

Fraction (LVEF) Shallow Exposure-Response Relationship Observed Pre-clinically Appears to Have Translated to Humans, May Enable Flexible Dose Optimization in Humans 0.0001 0.001 0.010 0.100 1.000 100 20 0 40 60 80 LVEF (% of Baseline) Free Plasma

Concentration ( moI/L) Dog Human

Phase 2 Clinical Trial Design Two

sequential dose-finding cohorts (with third cohort assessing patients on disopyramide) PK Echocardiogram Dose 1 Dose 2 Dose 3 Patients with symptomatic oHCM, and resting or provoked LVOT gradient 50 mmHg Study Visits Screen W-1 D1 W2 W4 W6

W9 W10 W12 W14 Screening Randomization CK-3773274 + SoC Placebo + SoC End of Study 1 2 IP Dosing Dose 1 Dose 2 Dose 3 Cohort 1 5 mg 10 mg 15 mg Cohort 2 10 mg 20 mg 30 mg

Patient Enrollment and Dosing 41

Total Enrolled Patients Final Dose Achieved (N) Cohort 1 Cohort 2 Placebo 5mg 10mg 15mg 10mg 20mg 30mg 13 4 5 5 9 4 1

Baseline Echocardiographic Data

Characteristic, mean Baseline (Day 1 Pre-dose) Placebo C1 + C2 Combined (N = 13) CK-274 Cohort 1 (N = 14) Cohort 2 (N = 14) LVEF (%) 74.5 73.2 75.4 LVOT-G, Rest (mmHg) 52.1 53.8 58.2 LVOT-G, Valsalva (mmHg) 84.6 74.4 82.3

High Response Rates on Treatment

with CK-274 1/13 11/14 13/14 Responder # / Total # Responder Definition: Resting LVOT-G <30 mmHg and post-Valsalva LVOT-G <50 mmHg at Week 10

Resting Left Ventricular Outflow

Tract Gradient Mean SEM Resting LVOT-G (mmHg) Baseline Week 2 Week 4 Week 6 Week 10 Placebo (n=13) 52.1 45.0 47.1 49.0 44.0 Cohort 1 (n = 14) 53.8 24.3 27.3 13.9 13.4 p-value vs placebo - 0.007 0.025 <0.0001 0.0003 Cohort 2 (n

= 14) 58.2 15.5 16.1 10.9 15.1 p-value vs placebo - 0.0002 0.0006 <0.0001 0.0004

Post-Valsalva Left Ventricular

Outflow Tract Gradient Mean SEM Valsalva LVOT-G (mmHg) Baseline Week 2 Week 4 Week 6 Week 10 Placebo (n=13) 84.6 71.3 71.3 73.4 76 Cohort 1 (n = 14) 74.4 51.3 46.1 37.1 38.1 p-value vs placebo - 0.097 0.038 0.0003 0.001 Cohort 2

(n = 14) 82.3 32.3 31.5 30.3 29.8 p-value vs placebo - 0.0005 0.0005 <0.0001 <0.0001

Safety Data Incidence of adverse

events on CK-274 similar to placebo and mild or moderate There were no treatment related serious adverse events reported by investigators No patients who received CK-274 in Cohort 1 had an LVEF <50% In Cohort 2, one patient with LVEF at baseline

of 58% was up titrated to 20 mg and experienced transient LVEF reduction to <50% (remaining above 40%) requiring down titration No interruptions or discontinuations of treatment with CK-274 occurred across both cohorts

Open Label Extension Trial

REDWOOD-HCM OLE open for eligible patients who completed REDWOOD-HCM Primary endpoint: incidence of AEs & LVEF <50 Secondary endpoints: measures of long-term effects of CK-274 on LVOT-G; assessments of steady-state pharmacokinetics. Cardiac

MRI sub-study to assess changes in cardiac morphology, function and fibrosis Individually optimized dose starts at lowest dose in prespecified range with echo-guided dose titration Initial dose and highest target dose informed by interim analyses

from REDWOOD-HCM OLE: Escalating doses based on echo-guided dose titration

Engaging Regulatory Authorities to

Inform Phase 3 Type C meeting with FDA to review Phase 3 clinical trial design End of Phase 2 meeting to review final dose selection rationale for Phase 3

Well tolerated dose with desired PD

effects oHCM patients Placebo Controlled Echocardiography Endpoints oHCM patients Exercise Endpoint (peak VO2) Extension study Long-term safety & efficacy SAD & MAD Healthy Volunteers Proof of activity in nHCM pts Pivotal study in nHCM IND

Filed NDA CK-274: Clinical Development Plan for HCM Improved LVOT gradient NDA: Potential for approval based on a single Ph3 study with an exercise endpoint Phase 1 Safety, PK & PD Phase 2 Proof of Concept, Dose Finding Phase 3 Pivotal

Novel Approach May Address Multiple

Unmet Patient Needs No FDA-approved therapies nHCM Non-Obstructive HCM HFpEF Heart Failure with Preserved Ejection Fraction Obstructive HCM oHCM CK-274 (Cardiac myosin Inhibitor)

CK-274: Collaborations &

Agreements RTW Investments, LP & Ji Xing Pharmaceuticals Limited RTW & Ji Xing Pharma Licensing Collaboration, Funding Commitments & Royalty Monetization RTW: Funding for Development of CK-274 Cytokinetics receives options for additional

funding for further development of CK-274 in HCMs: Eligible for $45M in each of 2 tranches (upon initiation of global registration programs in oHCM and nHCM) in exchange for 2% royalty on sales in U.S. & certain European countries If full $90M

received, Cytokinetics pays RTW 4% royalty on sales of CK-274 in U.S. & certain European countries, subject to royalty reductions for potential other indications RTW: Other Purchases RTW purchased Cytokinetics' royalty rights on future

sales of mavacamten for $85M RTW purchased $50M of Cytokinetics' common stock at $25 per share RTW Investments committed capital, funding and sale proceeds of $250M to Cytokinetics Ji Xing Pharma to develop & commercialize CK-274 in China,

subject to royalties and up to $200M in milestone payments RTW Investments purchased equity and royalty; provides access to capital for development of CK-274 Ji Xing Pharma Ji Xing to develop & commercialize CK-274 in Greater China and Taiwan

Cytokinetics receives $25M upfront; eligible to receive $200M in development & commercial milestones & double-digit royalties on sales of CK-274 in licensed territory IND filed in China; Phase 1 clinical trial underway; readying for

participation in Phase 3 clinical trial of CK-274 in oHCM

Sarcomere Directed Drug Development

Mozzafarian, et al. Circulation

2016; 133: e38-360 Number of cases (M) 2012 2030 +46% Heart Failure: Growing Prevalence and High Readmission Rates 6 million people have heart failure in the United States Prevalence Expected to Increase by 46% from 2012 - 2030 Initial

Hospitalization 24% readmitted <1 month post-discharge4,6 ~ 25-50% of patients expire or are re-hospitalized 60 days post-discharge7 44% readmitted <6 months post-discharge5 66% readmitted <12 months post-discharge3,8 1, Adams et al. Am

Heart J 2006; 149:209-16 2. Chen et al. JAMA 2011;306:1669-78 3. Dickstein et al. Eur Heart J 2008;29:2388-442 4. Korda,, et al. BMC Health Serv Res. 2017;21;17(1):220. 5. Krumholz et al. Arch Intern Med 1997;15799 - 105 6. Krumholz et al.

Circ Cardiovasc Qual Outcomes 2009;2(5):407-13 7. Loehr et al. Am J Cardiol 2008;101:1016-22 8. Whellan et al. Circulation 2010 Jan;3(1):33-40 1 of 2 hospitalized HF patients are readmitted within 6 months5

Pivotal Phase 3 Trial Design *An HF

event defined as the presentation of the subject for an urgent, unscheduled clinic/office/ED visit, or hospital admission, with a primary diagnosis of HF, where the patient exhibits new or worsening symptoms of HF on presentation, has objective

evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF (Hicks et al, 2015). Changes to oral diuretic therapy do not qualify as initiation or intensification of treatment. Landmark clinical trial

results published in NEJM Overview Enrolled 8,256 patients at ~1,000 sites in 35 countries Primary Endpoint Composite of time to cardiovascular (CV) death or first HF event*, whichever occurs first Secondary Endpoints Time to CV death Change in